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Sympathetic nervous system (SNS) activity is increased in polycystic ovary syndrome
(PCOS). Moxonidine is a centrally acting sympatholytic drug with known beneficial effects
on hypertension, insulin sensitivity, dyslipidemia and inflammation. In this double-blind
placebo controlled randomized clinical trial we examined the effect of moxonidine
on modulating sympathetic activity and downstream metabolic abnormalities in 48
pre-menopausal women with PCOS (Rotterdam diagnostic criteria), recruited from the
community (January 2013–August 2015). Participants received moxonidine (0.2mg daily
initially, up titrated to 0.4mg daily in 2 weeks) (n = 23) or placebo (n = 25) for 12 weeks.
Multiunit muscle sympathetic activity (by microneurography) and plasma noradrenaline
levels were measured (primary outcomes). Fasting lipids, insulin resistance, serum
androgens, and inflammatory markers were measured as secondary outcomes. Forty
three women completed the trial (19 moxonidine, 24 placebo). Mean change in burst
frequency (−3 ± 7 vs. −3 ± 8 per minute) and burst incidence (−3 ± 10 vs. −4 ± 12
per 100 heartbeat) did not differ significantly between moxonidine and placebo groups.
Women on moxonidine had a significant reduction in hs-CRP compared to placebo
group (−0.92 ± 2.3 vs. −0.04 ± 1.5) which did not persist post Bonferroni correction.
There was a significant association between markers of insulin resistance at baseline
and reduction in sympathetic activity with moxonidine. Moxonidine was not effective in
modulating sympathetic activity in PCOS. Anti-inflammatory effects of moxonidine and
a relationship between insulin resistance and sympathetic response to moxonidine are
suggested which need to be further explored.
Clinical Trial Registration Number: (NCT01504321)
Keywords: polycystic ovary syndrome, sympathetic nervous system, insulin resistance, moxonidine, randomized
controlled trial
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INTRODUCTION
Polycystic ovary syndrome (PCOS) is a common endocrinopathy
of reproductive age women, affecting 12–18%, with
hyperinsulinemia and hyperandrogenism being the key
hormonal features underpinning the pathophysiology of the
disease (Dunaif, 1997; March et al., 2010; Teede et al., 2011).
Additional to reproductive features, PCOS is associated with a
range of metabolic abnormalities including insulin resistance
(IR) and impaired glucose tolerance (IGT), gestational diabetes,
type 2 diabetes, dyslipidemia, obstructive sleep apnoea (OSA)
and an increased risk of cardiovascular disease (Teede et al., 2011;
Shorakae et al., 2014; Hart and Doherty, 2015). This increased
risk of cardiometabolic abnormalities in PCOS, at least in part,
is attributed to the interrelated effects of hyperandrogenism, IR,
sympathetic nervous system (SNS) dysfunction and chronic low
grade inflammation (Shorakae et al., 2015).
Increasing evidence arising from animal and human studies
favors the role of increased SNS activity in the pathophysiology
of PCOS (Lara et al., 1993, 2002; Greiner et al., 2005; Stener-
Victorin et al., 2005; Yildirir et al., 2006; Sverrisdottir et al.,
2008). A recent study by our group demonstrated increased
sympathetic drive, measured from multi- and single unit muscle
SNS activity (MSNA), in overweight and obese women with
PCOS, with the sympathoexcitation being independent of obesity
and other metabolic disturbances (Lambert et al., 2015). Others
have shown that modulation of SNS with electro-acupuncture,
effectively lowered the concentration of ovarian nerve growth
factor (NGF) (Stener-Victorin et al., 2000a) and improved insulin
sensitivity and lipid profile in PCOS animal models (Mannerås
et al., 2008; Johansson et al., 2010). Electro-acupuncture, physical
exercise and renal denervation have effectively modulated SNS in
women with PCOS and generated beneficial effects on ovulation,
hyperandrogenism and oligomenorrhea (Stener-Victorin et al.,
2000b, 2009; Jedel et al., 2011; Schlaich et al., 2011; Johansson
et al., 2013).
Moxonidine, an imidazoline 1 agonist, acts centrally to
modulate sympathetic activity and has previously been shown to
reduce sympathetic activity in obese hypertensive subjects (Esler
et al., 2004; Sanjuliani et al., 2006; Chazova and Schlaich, 2013)
and in young overweight, but otherwise healthy, males (Lambert
et al., 2017). Additional to inhibition of sympathetic drive,
Imidazoline 1 agonists have been demonstrated to beneficially
influence glucose and lipid metabolism and insulin sensitivity
(Haenni and Lithell, 1999; Chazova et al., 2006; Fenton et al.,
2006), hemodynamic and neuroendocrine parameters (Mitrovic
et al., 1991), endothelial dysfunction (Topal et al., 2006) and
inflammatory cytokine production (Pöyhönen-Alho et al., 2008)
when used in hypertensive, overweight and insulin resistant
subjects.
No data is available on moxonidine therapy and metabolic
outcomes in women with PCOS, a metabolic condition
underpinned by IR. Here, we aimed to study moxonidine
to preferentially target the sympathetic nervous system in
a randomized controlled trial in women with PCOS. We
hypothesized that central sympathoinhibition with moxonidine
would favorably modify sympathetic nervous activity (primary
outcome) and positively influence metabolic abnormalities
(secondary outcomes) in PCOS.
MATERIALS AND METHODS
Study Population and Design
In this double blind randomized placebo controlled
trial (NCT01504321), women with PCOS were recruited
through community advertisement between January 2013 and
March 2015. PCOS diagnosis and eligibility was confirmed
according to Rotterdam criteria, with presence of two of the
following three: oligo/anovulation (or cycle length <35 days),
clinical (hirsutism) or biochemical hyperandrogenism and
polycystic ovarian morphology on ultrasound (presence of 12
or more follicles measuring 2–9 mms in one or both ovaries)
(Group, 2004). Hirsutism was evaluated using a modified
Ferriman-Gallwey scoring (m-FG score) system (Yildiz et al.,
2010) and was defined as an m-FG score above 8 in Caucasian
and above 6 in Asian women.
This study protocol was approved by Ethics committees at the
Alfred Hospital and Monash Health. All subjects gave written
informed consent prior to participation.
Study Protocol
Overall 207 pre-menopausal women with history of PCOS
were assessed for eligibility. Eligibility criteria included BMI
20–40 kg/m2 and age 18–45 years old. Exclusion criteria
included pregnancy, diabetes, use of any medication that could
interfere with sympathetic nervous system activity (i.e. SNRI
antidepressants, α or β blocking anti-hypertensives) and insulin
resistance within the 3 months prior to recruitment, a history of
secondary hypertension (high blood pressure caused by another
medical condition), cardiovascular, cerebrovascular, renal, liver,
thyroid or lung disease and severe mental illness. Women who
were taking oral contraceptive pills (OCP) or metformin were
asked to stop the medication, use barrier contraception if desired
and if no contraindications, and to go through a 3 month wash
out period for OCP and 1 month washout period for metformin,
prior to recruitment. PCOS diagnosis was confirmed according
to the Rotterdam diagnostic criteria (Group, 2004).
Moxonidine and placebo capsules were prepared at the
Baker Heart & Diabetes Institute using commercially available
moxonidine tablets and lactose powder dispensed into identical
capsules. Participants were randomized by the Alfred Hospital
Clinical Trial Pharmacy and were allocated to the 12 weeks trial
intervention [moxonidine (0.2mg daily initially, up titrated to
0.4mg daily in 2 weeks) or placebo], between June 2013 and
August 2015 (Figure 1). Randomization was performed using a
simple block randomization with blocks of 10 (5 moxonidine
and 5 placebo in each block). All participants and investigators
remained blinded until after data lockdown and analysis of
results.
All participants attended the Baker Heart & Diabetes Institute
(at baseline and at completion of the trial) and the Monash
Center for Health Research and Implementation (at baseline, at
randomization and at the three follow up visits including one
after completion of the trial) for a total number of 7 visits across
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FIGURE 1 | Consort diagram of recruitment and study flow.
both sites. Clinical assessments, including all measurements,
were performed by a doctor at baseline and at completion
of the study. Body weight was measured in light clothes
without shoes, using a digital scale. The BMI was calculated
as weight (kg)/height squared (m2). Waist circumference was
measured at the midpoint between iliac crest and the lowest rib.
Total, peripheral, trunk and abdominal fat and lean mass were
determined by dual energy absorptiometry using a GE, Lunar
Prodigy DEXA scanner.
Muscle sympathetic nerve activity was assessed and analyzed
using methods reported previously (Lambert et al., 2015).
Recordings of multiunit postganglionic MSNA were made using
a tungsten microelectrode (FHC, Bowdoinham, ME, USA)
inserted directly into the right peroneal nerve at the fibular head.
During MSNA recording, blood pressure (BP) was measured
continuously using the Finometer system (Finapres Medical
System BV, Amsterdam, the Netherlands), and heart rate (HR)
was extracted from a 3-lead ECG. All of these parameters were
digitized with a sampling frequency of 1,000Hz (PowerLab
recording system, model ML 785/8SP; ADI Instruments, Bella
Vista, NSW, Australia). Resting measurements were recorded
over a 15-min period and averaged. Sympathetic bursts were
counted manually and expressed as burst frequency (bursts/min)
and burst incidence (bursts/100 heart beats).
Fasting blood samples were drawn from participants, at
baseline and at completion of the trial. Hormonal analyses were
performed at Monash Pathology, Monash Health and metabolic
determinations were performed at the Alfred Hospital Pathology.
The Access SHBG assay was performed using a sequential
two-step immunoenzymatic (“sandwich”) assay carried out on
a Beckman Coulter Unicel DXI 800 (Beckman Coulter, Lane
Cove, NSW, Australia). Testosterone assay was performed by
high performance liquid chromatography–mass spectrometry
(HPLCMS/MS) method using a liquid sample extraction (AB
Sciex Triple Quad 5500 LC/MS/MS system; Mt Waverley, Vic.,
Australia). Free Androgen Index (FAI) was calculated as (total
testosterone × 100)/SHBG. Plasma glucose and lipid profile
were quantified by automated enzymatic methods (Architect
C18000 analyser; Abbott Laboratories, Abbott Park, IL, USA),
insulin by radioimmunoassay (Linco Research, Inc., St. Charles,
MO, USA) and high-sensitivity C-reactive protein (hs-CRP) by
immunoturbidimetric assay (reference range<=5mg/L). Insulin
resistance was determined using Homeostatic Model Assessment
for insulin resistance (HOMA-IR), calculated as (fasting insulin
× fasting glucose/22.5). Plasma noradrenaline was determined
by high performance liquid chromatography with coulometric
detection as previously described (Lambert and Jonsdottir, 1998).
All medications were dispensed following randomization.
Participants were reviewed every 4 weeks for collection of
menstrual diary, measurement of waist and hip circumference
and weight and monitoring of heart rate and blood pressure.
Participants were screened for development of side effects via a
questionnaire at each follow up visit. Adherence to the allocated
intervention was assessed by counting the number of remaining
capsules in medication containers which were collected at each
follow up visit.
Statistical Analysis and Sample Size
Calculation
A sample size of 42 (21 subjects per treatment arm)was calculated
a priori with 80% power to demonstrate a difference in MSNA
(primary outcome) of 20% or greater (α = 0.05). This was based
on data from our previous work indicating that MSNA in young
overweight females is approximately 40 bursts per 100 heartbeats
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(standard deviation 9 bursts per 100 heartbeats) (Lambert et al.,
2007, 2013).
Data were analyzed using IBM SPSS Statistics, version 22
(Armonk, NY, USA). Data are presented asmean± SD ormedian
(IQR) if data were skewed. Histograms were used to determine
data distribution and skewed data were log transformed if
appropriate. Data were analyzed for primary and secondary
outcomes as per protocol. Absolute and relative change from
baseline were calculated for primary and secondary outcomes.
Student’s t test was used to compare between group differences
in mean absolute and relative change and paired t test was used
for comparison of within group differences. Non-parametric
methods were used for non-normally distributed variables. The
robustness of analyses was confirmed by conducting Bonferroni
correction several dependent and independent analysis. The
corrected p-value (0.002) was calculated as 0.05 divided by
number of tested variables (n = 23). Correlations with baseline
characteristics were determined using Pearson’s correlation
coefficient. To determine associations with change in the
primary outcome, regression analysis was performed including
parameters with significant correlation (p < 0.1) and significant
interaction with the study intervention (p < 0.1). All statistical
methods were confirmed with an experienced biostatistician.
Statistical significance was defined as a p ≤ 0.05.
RESULTS
Fifty-five women were recruited between January 2013 and
March 2015 and PCOS diagnosis was confirmed. Seven women
dropped out prior to randomization due to personal reasons.
Forty-eight women were randomized and allocated to the 3
months trial intervention [moxonidine (n = 23) or placebo
(n = 25)] between June 2013 and August 2015. Four women in
the moxonidine group discontinued the allocated intervention;
one woman became pregnant, one developed a skin rash
(considered unrelated to the trial intervention) and two dropped
out due to personal reasons. One woman in the placebo
group withdrew from the trial prior to receiving the allocated
intervention. Nineteen women in the moxonidine group and 24
women in the placebo group received the allocated intervention
for 3 months and were analyzed for the primary and secondary
outcomes (Figure 1).
Baseline Characteristics
The anthropometric, haemodynamic, metabolic, and hormonal
characteristics of participants are presented in Table 1. Overall,
there were no differences in baseline characteristics between the
two groups.
Effect on Sympathetic Activity
Due to technical difficulties in obtaining a suitable recording
site, only 31 participants (13 in the moxonidine group and 18
in the placebo group) completed MSNA assessments pre and
post intervention. Mean absolute and relative changes in burst
frequency, burst incidence and plasma noradrenaline levels were
not different between the two groups (Table 2).
TABLE 1 | Baseline characteristics of participants in each group.





Age (years) 31 ± 6 29 ± 6
ANTHROPOMETRIC
Weight (kg) 80 ± 15 78 ± 17
BMI (kg/m2) 30 ± 5 29 ± 6
WC (cm) 102 ± 13 101 ± 16
WHR 0.97 ± 0.05 0.95 ± 0.06
Body fat (%) 43 ± 10 43 ± 9
HAEMODYNAMIC
SBP (mmHg) 109(12) 108(9)
DBP (mmHg) 71 ± 10 69 ± 8
HR (per minute) 63 ± 8 66 ± 10
METABOLIC
Fasting insulin (µU/ml) 19.4 ± 11.1 15.0 ± 4.5
Fasting glucose (mmol/L) 4.6 ± 0.6 4.6 ± 0.3
Post OGTT insulin (µU/ml) 84.9 ± 57.8 89.8 ± 52.3
Post OGTT glucose (mmol/L) 5.8 ± 1.5 5.2 ± 1.2
HOMA-IR 4.0(3.9) 3.4(2.1)
TC (mmol/L) 4.8 ± 0.8 4.8 ± 0.8
TG (mmol/L) 1.2 ± 0.7 0.9 ± 0.4
HDL (mmol/L) 1.4 ± 0.3 1.5 ± 0.4
LDL (mmol/L) 2.9 ± 0.8 3.0 ± 0.8
hs_CRP (mg/L) 2.2(3.1) 2.6(4.3)
REPRODUCTIVE
Total testosterone (nmol/L) 1.5 ± 0.7 1.4 ± 0.7
SHBG (nmol/L) 39 ± 17 49 ± 19
FAI 5 ± 4.3 3.3 ± 2
FG-score 13 ± 5 14 ± 6
Skewed data are presented as median (IQR) and log transformed data were included in
the analysis. All p-values for differences between the groups were non-significant.
BMI, body mass index; WC, waist circumference; WHR, waist to hip ratio; SBP, systolic
blood pressure; DBP, diastolic blood pressure; HR, heart rate; OGTT, oral glucose
tolerance test; HOMA-IR, homeostatic model of assessment of insulin resistance; TC,
total cholesterol; TG, triglycerides; HDL-C, high density lipoprotein cholesterol; LDL-C,
low density lipoprotein cholesterol; hs-CRP, high sensitivity C-reactive protein; DHEAS,
dehydroepiandrosterone sulfate; SHBG, sex hormone binding globulin; FAI, free androgen
index.
Effect on Haemodynamic Parameters
Mean absolute and relative change in SBP, DBP and HR were not
different between the two groups (Table 2).
Effect on Lipid Profile
The mean absolute (−0.1± 0.3 vs. 0.2± 0.6, p= 0.05 for TC and
−0.1± 0.4 vs. 0.1± 0.3, p= 0.05 for TG respectively) and relative
change (−2 ± 7% vs. 4 ± 12%, p = 0.05 for TC, −4 ± 30% vs.
19 ± 33%, p = 0.02 for TG and −2 ± 10% vs. 8 ± 18%, p = 0.04
for LDL-C respectively) were different between the placebo and
moxonidine groups (Table 2). These became non-significant post
Bonferroni correction for number of analysis (p > 0.002).
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TABLE 2 | Sympathetic, anthropometric, haemodynamic, metabolic, inflammatory, and reproductive parameters before and after 3 months of intervention in each group.















n = 18 n = 13
Burst frequency (per minute) 28(9) 26(9) NS 27 ± 9 23 ± 8 NS NS NS NS
Burst incidence (per 100
heartbeat)
44(12) 41(13) NS 40 ± 12 37 ± 11 NS NS NS NS
Noradrenaline (pg/ml) 254(149) 244(149) NS 277 ± 125 291 ± 166 NS NS NS NS
Anthropometric parameter(s) n = 24 n = 19
Weight (Kg) 80 ± 15 81 ± 15 NS 78 ± 17 79 ± 17 NS NS NS NS
BMI (Kg/m2) 30 ± 5 30 ± 5 NS 29 ± 6 29 ± 6 NS NS NS NS
WHR 0.97 ± 0.05 0.96 ± 0.04 NS 0.95 ± 0.06 0.96 ± 0.06 NS NS NS NS
Body fat (%) 43 ± 10 42 ± 9 NS 46(9) 44(9) NS NS NS NS
Haemodynamic parameter(s) n = 23 n = 19
SBP (mmHg) 109 ± 10 110 ± 11 NS 108(9) 109(15) NS NS NS NS
DBP (mmHg) 70(10) 68(15) NS 69 ± 8 69 ± 8 NS NS NS NS
HR (per minute) 64 ± 8 62 ± 8 NS 66 ± 10 62 ± 8 NS NS NS NS
Metabolic parameter(s) n = 22 n = 19
Fasting glucose (mmol/L) 4.6(0.7) 4.6(0.7) NS 4.6 ± 0.4 4.6 ± 0.3 NS NS NS NS
Post OGTT glucose (mmol/L) 5.5(2.1) 5.8(2.5) NS 5.8 ± 1.3 5.3 ± 1.2 NS NS NS NS
Fasting insulin (µU/ml) 23.2 ± 15.2 19.4 ± 11.13 NS 17 ± 7.2 14.9 ± 4.5 NS NS NS NS
Post OGTT insulin (µU/ml) 74.9(99.4) 64.7(96.9) NS 86.9 ± 53.6 89.8 ± 52.3 NS NS NS NS
HOMA-IR 4(5.2) 3.2(3.2) NS 3.5 ± 1.5 3 ± 0.9 NS NS NS NS
TC (mmol/L) 4.5(1.4) 4.4(1.3) NS 4.8 ± 0.8 4.9 ± 0.8 NS NS 0.05 0.05
TG (mmol/L) 0.9(1.0) 0.9(0.7) NS 0.8(0.5) 0.9(0.4) NS NS 0.05 0.02
HDL (mmol/L) 1.4 ± 0.3 1.4 ± 0.2 NS 1.5(0.5) 1.3(0.7) NS NS NS NS
LDL (mmol/L) 2.9 ± 0.8 2.8 ± 0.7 NS 2.9 ± 0.8 3.1 ± 0.7 NS NS NS 0.04
Inflammatory parameter(s) n = 22 n = 18
hs-CRP (mg/L) 2.4(3.4) 1.6(5.5) NS 2.1(4.2) 1.4(4.3) 0.004 NS NS 0.02
Reproductive parameter(s) n = 22 n = 19
Testosterone (nmol/L) 1.4 ± 0.7 1.3 ± 0.8 NS 1.1(0.9) 1.3(0.7) NS NS NS NS
SHBG (nmol/L) 37 ± 16 42 ± 20 0.005 49 ± 19 53 ± 20 0.03 NS NS NS
FAI 3.9(3.8) 3.1(3.9) NS 2.6(2.8) 2.3(2.3) NS NS NS NS
Skewed data are presented as median (IQR) and non-parametric methods were used for analysis.
ap-value for within group comparison of pre vs. post intervention data.
bp-value for between group (moxonidine vs. placebo) comparison of post intervention data.
cp-value for between group (moxonidine vs. placebo) comparison of absolute change from baseline.
dp-value for between group (moxonidine vs. placebo) comparison of relative change from baseline.
BMI, body mass index; WHR, waist to hip ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; OGTT, oral glucose tolerance test; HOMA-IR, homeostatic
model of assessment of insulin resistance; TC, total cholesterol; TG, triglycerides; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; hs-CRP, high
sensitivity C-reactive protein; DHEAS, dehydroepiandrosterone sulfate; SHBG, sex hormone binding globulin; FAI, free androgen index.
Effect on Inflammatory Markers
There was a reduction in hs-CRP within the moxonidine group
[2.1(4.2) vs. 1.4(4.3), p = 0.004] and the mean relative change
in hs-CRP was different between the placebo and moxonidine
groups (Table 2). These became non-significant post Bonferroni
correction for number of analysis (p > 0.002).
Effect on Reproductive Hormone Profile
SHBG increased within both moxonidine and placebo groups (49
± 19 vs. 53 ± 20, p = 0.03 and 37 ± 16 vs. 42 ± 20, p = 0.005
respectively) which became non-significant post Bonferroni
correction for number of analysis (p > 0.002) (Table 2). The
mean absolute and relative change were not different between the
two groups.
Associations With Change in Sympathetic
Function
In themoxonidine group, reduction in burst frequency correlated
with fasting insulin, post OGTT insulin and post OGTT glucose
at baseline. Reduction in burst incidence also correlated with
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fasting insulin and HOMA-IR at baseline (Table 3, Figure 2).
There was no correlation of change in MSNA with markers of
insulin resistance in the placebo group. We tested for interaction
between the markers of insulin resistance and intervention
in sympathetic response to moxonidine. The interaction was
significant for post OGTT glucose (p = 0.04) and approached
significance for fasting insulin (p = 0.06) when tested for mean
change in burst frequency. It was significant for fasting insulin
(p = 0.03) and HOMA-IR (p = 0.03) when tested for mean
change in burst incidence.
On univariate regression analysis in the moxonidine group
mean change in burst frequency was significantly associated with
post OGTT glucose and fasting insulin and mean change in
burst incidence was significantly associated with fasting insulin
and HOMA-IR at baseline. All p-values were non-significant
(p > 0.1) for the placebo group.
Adherence to Allocated Intervention and
Adverse Effects
Ten participants (6 in the placebo group and 4 in the moxonidine
group) failed to return the empty medication containers for
assessment of adherence to intervention. In the remaining
participants, adherence to the allocated intervention was 97% in
themoxonidine group and 100% in the placebo group. No serious
adverse events were reported. The most commonly reported
side effects across all visits included lack of energy (54%), dry
mouth (52%), headache (44%), drowsiness (38%), and sleep
difficulties (34%) in the moxonidine group and lack of energy
(64%), headache (55%), dry mouth (48%), drowsiness (43%), and
sleep difficulties (41%) in the placebo group respectively. The
frequency of reported side effects did not change significantly as
the trial progressed (Supplementary Table 1).
DISCUSSION
In this study, we investigated the effect of moxonidine on
modulating sympathetic activity and downstream metabolic
abnormalities in a 12 weeks double blind randomized placebo
controlled trial of moxonidine vs. placebo in 48 pre-menopausal
women with PCOS. We found that moxonidine did not reduce
sympathetic activity when compared to placebo in women
with PCOS. Women on moxonidine had a reduction in hs-
CRP compared to the placebo group which became non-
significant post Bonferroni correction. Total cholesterol, LDL
and triglyceride levels slightly increased in the moxonidine group
and decreased in the placebo group which did not reach statistical
significance. We found a significant interaction between markers
of insulin resistance and reduction in sympathetic activity with
moxonidine.
Ovarian sympathetic activity is most likely increased in
polycystic ovaries. Human studies have demonstrated a higher
density of catecholaminergic fibers in polycystic ovaries (Heider
et al., 2001). Moreover, human (Dissen et al., 2009) and animal
(Lara et al., 2000) studies have demonstrated an association
between increased intra-ovarian synthesis of nerve growth
factor (NGF) and polycystic ovaries. While increased ovarian
sympathetic activity results in increased intra-ovarian androgen
synthesis in response to gonadotrophins (Barria et al., 1993),
some evidence suggests the increased ovarian sympathetic
outflow may even precede development of arrested follicles
in polycystic ovaries (Lara et al., 1993). In an experimental
model sympathetic denervation of the ovary prevented the
development of ovarian cysts (Barria et al., 1993). Previous
interventions using low frequency electro-acupuncture and renal
denervation modulated sympathetic over activity in women with
PCOS with reduction in MSNA and noradrenaline spillover
to plasma (Stener-Victorin et al., 2009; Jedel et al., 2011;
Schlaich et al., 2011). Considering both of these procedures
offer discrete and organ specific alterations in sympathetic
tone, including at the level of ovaries with electroacupuncture
(Stener-Victorin et al., 2003, 2004, 2006), it is plausible that
the increased sympathetic tone previously documented in
women with PCOS (Sverrisdottir et al., 2008; Lambert et al.,
2015) also included activation of the sympathetic drive to the
ovaries.
Moxonidine effectively reduced MSNA and noradrenaline
levels, in comparison to placebo, when trialed in insulin resistant,
overweight/obese or hypertensive participants (Greenwood et al.,
2000; Sanjuliani et al., 2006; Dorresteijn et al., 2013) with variable
metabolic and haemodynamic effects (Haenni and Lithell, 1999;
Chazova et al., 2006; Sanjuliani et al., 2006; Topal et al., 2006;
Dorresteijn et al., 2013; Lambert et al., 2017). When trialed in
young, overweight men, moxonidine 0.4 mg/day for 24 weeks
resulted in reduction in MSNA and substantially decreased the
clinic systolic BP but failed to improve metabolic parameters
(Lambert et al., 2017). The contributors to the lack of effect of
moxonidine on MSNA in the present study are unclear. With
72% of participants completed MSNA assessments pre and post
intervention, we were 86% powered to detect a 25% reduction
in sympathetic activity in this study. Given the high level of
adherence to study medication in both groups, the lack of effect
of moxonidine on MSNA suggests either we were underpowered
to detect a smaller reduction of <25% in SNS activity by
moxonidine, or that the sympathetic drive in women with PCOS,
at least in part, has its origins in brain regions other than those
influenced by imidazoline agonists; with further research needed
in future. Moreover MSNA is affected by sex and age (Ng et al.,
1993) and is influenced by visceral adiposity (Alvarez et al., 2002)
and phase of the ovarian cycle (Carter et al., 2013). The potential
role of these factors influencing the physiological response to
moxonidine in women with PCOS also remains unknown and
deserves further attention.
There is a close inter-relation between insulin sensitivity
and sympathetic activity, with insulin resistance and
hyperinsulinemia being associated with SNS over activity
(Kaaja and Poyhonen-Alho, 2006; Dampney, 2011). In our
study, the magnitude of change in MSNA correlated significantly
with baseline insulin resistance in the moxonidine group. We
demonstrated that mean change in burst frequency significantly
correlated with post OGTT glucose and fasting insulin and
mean change in burst incidence significantly correlated with
fasting insulin and HOMA-IR at baseline. This is consistent with
previous studies demonstrating the effectiveness of moxonidine
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TABLE 3 | Correlation of baseline insulin sensitivity with magnitude of change in sympathetic function in moxonidine group.









Correlation analysis R −0.608 −0.546 −0.633 −0.522
P-value 0.03 0.05 0.02 0.07
Interaction with the study intervention P-value 0.04 0.06 0.09 0.08
Univariate regression analysis R2 0.4 0.3 0.4 0.3
B coefficient −3.1 −0.6 −0.1 −2.9
P-value 0.03 0.05 0.02 0.07
Mean change in
Burst incidence
Correlation analysis R −0.451 −0.648 −0.433 −0.628
[-9pt] P-value 0.1 0.017 0.1 0.02
Interaction with the study intervention P-value 0.09 0.03 0.2 0.03
Univariate regression analysis R2 0.2 0.4 0.2 0.4
B coefficient −3.6 −1.1 −0.1 −5.6
P-value 0.1 0.02 0.1 0.02
OGTT, oral glucose tolerance test; HOMA-IR, homeostatic model of assessment of insulin resistance.
FIGURE 2 | Correlation of HOMA-IR with magnitude of change in burst incidence and burst frequency in Moxonidine vs. placebo group. In the moxonidine group,
reduction in burst incidence (A) and burst frequency (B) correlated with HOMA-IR at baseline. There was no correlation of change in MSNA with baseline HOMA-IR in
the placebo group (C,D).
in improving sympathetic and haemodynamic profiles in insulin
resistant populations (Sanjuliani et al., 2006; Dorresteijn et al.,
2013).
It is reported previously that total cholesterol and triglyceride
levels significantly reduced (Lumb et al., 2004; Ebinç et al., 2008)
or remained unchanged (Elisaf et al., 1999) with moxonidine
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in overweight and obese hypertensive participants. In this study
a small, non-clinically significant deterioration in fasting lipids
is shown in the moxonidine group. Clearly the impact of
moxonidine on fasting lipid profile remains unclear. Moxonidine
has reduced circulating TNF-α and IL-6 levels in spontaneously
hypertensive rat models suggestive of a potential direct effect
on cytokine signaling and inflammation (Aceros et al., 2011).
Moxonidine has also resulted in reduction in TNF-α levels
in 87 overweight postmenopausal women with hypertension
(Pöyhönen-Alho et al., 2008). In our study, women on
moxonidine had reduction in hs-CRP levels which became non-
significant post Bonferroni correction. While this is potentially
is explained by our small sample size and lack of power for
detection of a change in this secondary outcome, the clinical
relevance of such finding and a potential modulatory effect of
moxonidine on inflammation needs to be explored further in
future studies.
Strength and Limitations
To the best of our knowledge, our study is the first double
blind randomized clinical trial of pharmacological sympathetic
modulation, in this case with moxonidine vs. placebo, in
women with PCOS. The women were community recruited
and we followed a robust methodology including using the
gold standard microneurography for direct measurement of
sympathetic activity. Although microneurography is a powerful
technique, obtaining an appropriate recording site, particularly in
overweight subjects, can be challenging for both the investigator
and participant. Further limitations include the use of indirect
measures of insulin resistance and that participant recruitment
and maintenance throughout the study was difficult given the
large commitment required.
CONCLUSION
Overall moxonidine was not effective in modulating sympathetic
activity in women with PCOS based on this study. We
found a significant relationship between insulin resistance and
sympathetic response to moxonidine, suggesting large clinical
trials are needed to evaluate the effectiveness of this medication
potentially targeting the most insulin resistant PCOS cases. We
also report an anti-inflammatory effect of moxonidine in women
with PCOS which needs further exploration in terms of the
underlying mechanistic pathways.
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